0 XP   0   0   0

Epigenomics AG
Buy or Sell?

Welcome Invester! I guess you are interested in Epigenomics AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's start. I'm going to help you getting a better view of Epigenomics AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Epigenomics AG even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Epigenomics AG is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Epigenomics AG. The closing price on 2022-09-28 was $2.39 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Epigenomics AG Daily Candlestick Chart


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Epigenomics AG.

1.1. Profitability

An important factor of a company's health is the profitability.

1.1.1. Net Profit Margin

Measures how much net profit Epigenomics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Epigenomics to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -1,063.4% means that $-10.63 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Epigenomics AG:

  • The MRQ is -1,032.5%. The company is making a huge loss. -2
  • The TTM is -1,063.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,032.5%TTM-1,063.4%+30.9%
TTM-1,063.4%YOY-1,308.9%+245.5%
TTM-1,063.4%5Y-1,279.4%+215.9%
5Y-1,279.4%10Y-1,223.1%-56.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,032.5%-6.7%-1,025.8%
TTM-1,063.4%-1.7%-1,061.7%
YOY-1,308.9%1.9%-1,310.8%
5Y-1,279.4%-5.4%-1,274.0%
10Y-1,223.1%-1.4%-1,221.7%
1.1.2. Return on Assets

Shows how efficient Epigenomics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Epigenomics to the Diagnostics & Research industry mean.
  • -3.7% Return on Assets means that Epigenomics generated $-0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Epigenomics AG:

  • The MRQ is -6.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.3%TTM-3.7%-2.6%
TTM-3.7%YOY-26.4%+22.8%
TTM-3.7%5Y-19.3%+15.6%
5Y-19.3%10Y-18.9%-0.3%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.3%-0.3%-6.0%
TTM-3.7%-0.2%-3.5%
YOY-26.4%0.3%-26.7%
5Y-19.3%-0.6%-18.7%
10Y-18.9%-0.8%-18.1%
1.1.3. Return on Equity

Shows how efficient Epigenomics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Epigenomics to the Diagnostics & Research industry mean.
  • -7.8% Return on Equity means the company generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Epigenomics AG:

  • The MRQ is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-4.5%-3.3%
TTM-4.5%YOY-42.9%+38.4%
TTM-4.5%5Y-35.7%+31.2%
5Y-35.7%10Y-34.2%-1.5%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.8%1.0%-8.8%
TTM-4.5%0.5%-5.0%
YOY-42.9%1.1%-44.0%
5Y-35.7%-0.5%-35.2%
10Y-34.2%-0.5%-33.7%

1.2. Operating Efficiency of Epigenomics AG.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Epigenomics is operating .

  • Measures how much profit Epigenomics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Epigenomics to the Diagnostics & Research industry mean.
  • An Operating Margin of -2,542.9% means the company generated $-25.43  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Epigenomics AG:

  • The MRQ is -2,542.9%. The company is operating very inefficient. -2
  • The TTM is -1,817.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,542.9%TTM-1,817.9%-725.0%
TTM-1,817.9%YOY-1,238.8%-579.1%
TTM-1,817.9%5Y-1,339.2%-478.6%
5Y-1,339.2%10Y-1,289.2%-50.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,542.9%-2.2%-2,540.7%
TTM-1,817.9%0.5%-1,818.4%
YOY-1,238.8%2.9%-1,241.7%
5Y-1,339.2%-1.3%-1,337.9%
10Y-1,289.2%0.7%-1,289.9%
1.2.2. Operating Ratio

Measures how efficient Epigenomics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 3,165.1% means that the operating costs are $31.65for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Epigenomics AG:

  • The MRQ is 31.651. The company is inefficient in keeping operating costs low. -1
  • The TTM is 20.579. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ31.651TTM20.579+11.072
TTM20.579YOY16.020+4.559
TTM20.5795Y15.934+4.645
5Y15.93410Y14.728+1.206
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ31.6511.390+30.261
TTM20.5791.257+19.322
YOY16.0201.240+14.780
5Y15.9341.140+14.794
10Y14.7281.100+13.628

1.3. Liquidity of Epigenomics AG.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Epigenomics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 584.0% means the company has $5.84 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Epigenomics AG:

  • The MRQ is 5.840. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.012. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.840TTM9.012-3.173
TTM9.012YOY2.814+6.198
TTM9.0125Y4.052+4.961
5Y4.05210Y3.974+0.078
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ5.8402.320+3.520
TTM9.0122.526+6.486
YOY2.8142.728+0.086
5Y4.0522.587+1.465
10Y3.9742.811+1.163
1.3.2. Quick Ratio

Measures if Epigenomics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy (always compare to Diagnostics & Research industry mean)
  • A Quick Ratio of 6.4% means the company can pay off $0.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Epigenomics AG:

  • The MRQ is 0.064. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.233. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.064TTM0.233-0.169
TTM0.233YOY0.284-0.050
TTM0.2335Y0.261-0.027
5Y0.26110Y0.296-0.036
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0641.213-1.149
TTM0.2331.378-1.145
YOY0.2841.510-1.226
5Y0.2611.358-1.097
10Y0.2961.389-1.093

1.4. Solvency of Epigenomics AG.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Epigenomics assets are financed with debt.

  • Below 1 (100%) is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Debt to Asset Ratio of 0.19 means that Epigenomics assets are financed with 19.2% credit (debt) and the remaining percentage (100% - 19.2%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Epigenomics AG:

  • The MRQ is 0.192. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.137. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.192TTM0.137+0.055
TTM0.137YOY0.366-0.230
TTM0.1375Y0.347-0.210
5Y0.34710Y0.334+0.013
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1920.408-0.216
TTM0.1370.404-0.267
YOY0.3660.444-0.078
5Y0.3470.459-0.112
10Y0.3340.452-0.118
1.4.2. Debt to Equity Ratio

Measures if Epigenomics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Debt to Equity ratio of 23.7% means that company has $0.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Epigenomics AG:

  • The MRQ is 0.237. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.161. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.237TTM0.161+0.077
TTM0.161YOY0.585-0.425
TTM0.1615Y0.753-0.593
5Y0.75310Y0.700+0.053
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2370.639-0.402
TTM0.1610.624-0.463
YOY0.5850.666-0.081
5Y0.7530.753+0.000
10Y0.7000.774-0.074

2. Market Valuation of Epigenomics AG

2. Earnings
2.1. Price to Earnings Ratio

Measures how many years it takes to double your invested money in Epigenomics.

  • Above 15 is considered overpriced but is hard to determine (always use industry average).
  • A PE ratio of -24.59 means the investor is paying $-24.59 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Epigenomics AG:

  • The EOD is -20.987. Company is losing money. -2
  • The MRQ is -24.587. Company is losing money. -2
  • The TTM is -18.601. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-20.987MRQ-24.587+3.600
MRQ-24.587TTM-18.601-5.986
TTM-18.601YOY-7.041-11.560
TTM-18.6015Y-6.057-12.544
5Y-6.05710Y-5.267-0.790
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-20.987-0.297-20.690
MRQ-24.587-0.489-24.098
TTM-18.601-1.203-17.398
YOY-7.0411.466-8.507
5Y-6.057-0.471-5.586
10Y-5.267-0.101-5.166
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Epigenomics.

  • Lower is better
  • A PEG ratio of 1 means the investor is paying a fair price for the stock

Let's take a look of the Price Earnings to Growth Ratio trends of Epigenomics AG:

  • The MRQ is 0.270. Very good. +2
  • The TTM is 0.218. Very good. +2
Trends
Current periodCompared to+/- 
MRQ0.270TTM0.218+0.051
TTM0.218YOY0.185+0.033
TTM0.2185Y0.134+0.084
5Y0.13410Y0.1340.000
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2700.013+0.257
TTM0.2180.046+0.172
YOY0.1850.115+0.070
5Y0.1340.039+0.095
10Y0.1340.043+0.091

2. Books
2.3. Price to Book Ratio

Measures if the stock price of Epigenomics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 2.75 means the investor is paying $2.75 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Epigenomics AG:

  • The EOD is 2.346. Good. +1
  • The MRQ is 2.748. Good. +1
  • The TTM is 3.661. Neutral. Compare to industry.
Trends
Current periodCompared to+/- 
EOD2.346MRQ2.748-0.402
MRQ2.748TTM3.661-0.913
TTM3.661YOY20.346-16.684
TTM3.6615Y5.316-1.655
5Y5.31610Y4.623+0.693
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD2.3462.069+0.277
MRQ2.7482.239+0.509
TTM3.6613.132+0.529
YOY20.3464.289+16.057
5Y5.3163.318+1.998
10Y4.6233.015+1.608

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Epigenomics AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Gains Per Share---0.1480.120-223%-0.170+15%0.093-260%0.093-260%
Book Value Per Share--1.0191.415-28%0.796+28%0.644+58%0.560+82%
Current Ratio--5.8409.012-35%2.814+107%4.052+44%3.974+47%
Debt To Asset Ratio--0.1920.137+40%0.366-48%0.347-45%0.334-43%
Debt To Equity Ratio--0.2370.161+48%0.585-59%0.753-69%0.700-66%
Dividend Per Share----0%-0%-0%-0%
Eps---0.080-0.028-64%-0.321+304%-0.664+735%-0.708+790%
Gains Per Share---0.1480.120-223%-0.170+15%0.093-260%0.093-260%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---10.325-10.634+3%-13.089+27%-12.794+24%-12.231+18%
Operating Margin---25.429-18.179-29%-12.388-51%-13.392-47%-12.892-49%
Operating Ratio--31.65120.579+54%16.020+98%15.934+99%14.728+115%
Pb Ratio2.346-17%2.7483.661-25%20.346-86%5.316-48%4.623-41%
Pe Ratio-20.987+15%-24.587-18.601-24%-7.041-71%-6.057-75%-5.267-79%
Peg Ratio--0.2700.218+24%0.185+46%0.134+101%0.134+101%
Price Per Share2.390-17%2.8005.878-52%13.795-80%7.691-64%9.453-70%
Quick Ratio--0.0640.233-73%0.284-77%0.261-75%0.296-78%
Return On Assets---0.063-0.037-42%-0.264+319%-0.193+205%-0.189+200%
Return On Equity---0.078-0.045-43%-0.429+449%-0.357+357%-0.342+338%
 EOD+2 -1MRQTTM+4 -13YOY+13 -45Y+11 -610Y+11 -6

3.2. Fundamental Score

Let's check the fundamental score of Epigenomics AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-20.987
Price to Book Ratio (EOD)Between0-12.346
Net Profit Margin (MRQ)Greater than0-10.325
Operating Margin (MRQ)Greater than0-25.429
Quick Ratio (MRQ)Greater than10.064
Current Ratio (MRQ)Greater than15.840
Debt to Asset Ratio (MRQ)Less than10.192
Debt to Equity Ratio (MRQ)Less than10.237
Return on Equity (MRQ)Greater than0.15-0.078
Return on Assets (MRQ)Greater than0.05-0.063
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Epigenomics AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5020.869
Ma 20Greater thanMa 502.575
Ma 50Greater thanMa 1002.710
Ma 100Greater thanMa 2002.755
OpenGreater thanClose2.390
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets20,620
Total Liabilities3,954
Total Stockholder Equity16,666
 As reported
Total Liabilities 3,954
Total Stockholder Equity+ 16,666
Total Assets = 20,620

Assets

Total Assets20,620
Total Current Assets18,769
Long-term Assets18,769
Total Current Assets
Cash And Cash Equivalents 18,043
Net Receivables 206
Inventory 77
Other Current Assets 36
Total Current Assets  (as reported)18,769
Total Current Assets  (calculated)18,362
+/- 407
Long-term Assets
Property Plant Equipment 1,762
Intangible Assets 89
Long-term Assets  (as reported)1,851
Long-term Assets  (calculated)1,851
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities3,214
Long-term Liabilities740
Total Stockholder Equity16,666
Total Current Liabilities
Accounts payable 714
Other Current Liabilities 820
Total Current Liabilities  (as reported)3,214
Total Current Liabilities  (calculated)1,534
+/- 1,680
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,006
Deferred Long Term Liability 44
Long-term Liabilities  (as reported)740
Long-term Liabilities  (calculated)1,050
+/- 310
Total Stockholder Equity
Common Stock16,357
Retained Earnings -97,117
Other Stockholders Equity 97,426
Total Stockholder Equity (as reported)16,666
Total Stockholder Equity (calculated)16,666
+/-0
Other
Capital Stock16,357
Common Stock Shares Outstanding 16,357
Net Invested Capital 16,666
Net Tangible Assets 16,621
Net Working Capital 15,555



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
19,220
16,410
12,847
22,384
19,773
16,695
14,166
12,488
21,827
18,657
15,547
12,963
13,989
13,551
11,041
8,830
6,797
9,499
9,690
27,011
24,663
22,438
20,620
20,62022,43824,66327,0119,6909,4996,7978,83011,04113,55113,98912,96315,54718,65721,82712,48814,16616,69519,77322,38412,84716,41019,220
   > Total Current Assets 
16,035
12,947
9,245
18,549
16,859
13,703
10,977
9,116
18,274
14,185
10,562
7,716
12,123
11,803
9,435
7,364
5,469
8,398
8,662
26,027
23,712
20,811
18,769
18,76920,81123,71226,0278,6628,3985,4697,3649,43511,80312,1237,71610,56214,18518,2749,11610,97713,70316,85918,5499,24512,94716,035
       Cash And Cash Equivalents 
12,163
10,553
6,802
15,993
12,826
10,316
8,579
5,829
16,487
12,126
8,437
5,501
10,155
10,252
7,722
5,735
3,485
7,446
6,949
23,555
22,963
20,039
18,043
18,04320,03922,96323,5556,9497,4463,4855,7357,72210,25210,1555,5018,43712,12616,4875,8298,57910,31612,82615,9936,80210,55312,163
       Short-term Investments 
794
925
880
882
905
897
801
803
653
747
700
776
880
731
854
905
961
0
0
0
0
0
0
000000961905854731880776700747653803801897905882880925794
       Net Receivables 
2,371
265
882
174
2,061
309
651
835
371
132
326
282
473
73
281
91
474
53
457
1,769
201
57
206
206572011,7694575347491281734732823261323718356513092,0611748822652,371
       Inventory 
271
503
293
243
293
351
358
289
364
462
422
302
313
291
241
197
122
279
242
273
176
115
77
77115176273242279122197241291313302422462364289358351293243293503271
       Other Current Assets 
437
701
388
1,257
774
1,830
28
1,360
399
718
40
855
302
456
23
436
32
620
21
430
64
600
36
3660064430216203243623456302855407183991,360281,8307741,257388701437
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
4,472
4,985
5,247
1,866
1,748
1,606
1,466
1,328
1,101
1,028
984
951
1,627
1,851
1,8511,6279519841,0281,1011,3281,4661,6061,7481,8665,2474,9854,472000000000
       Property Plant Equipment 
752
752
676
774
720
731
713
719
701
1,353
1,686
1,626
1,533
1,460
1,367
1,275
1,184
1,004
959
920
891
1,571
1,762
1,7621,5718919209591,0041,1841,2751,3671,4601,5331,6261,6861,353701719713731720774676752752
       Intangible Assets 
796
732
240
850
204
606
170
512
144
439
141
368
333
288
239
0
145
0
69
0
60
0
89
8906006901450239288333368141439144512170606204850240732796
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
4,472
4,985
5,247
1,866
1,748
0
0
-1
0
0
0
0
0
0
000000-1001,7481,8665,2474,9854,472000000000
> Total Liabilities 
4,006
3,291
4,377
9,379
9,196
9,010
9,126
10,111
3,214
2,872
3,844
4,038
4,360
7,279
3,724
3,286
2,933
3,020
3,329
2,777
2,543
3,351
3,954
3,9543,3512,5432,7773,3293,0202,9333,2863,7247,2794,3604,0383,8442,8723,21410,1119,1269,0109,1969,3794,3773,2914,006
   > Total Current Liabilities 
3,912
3,181
4,222
9,280
9,153
8,967
9,083
10,067
3,167
2,226
2,993
3,232
3,619
6,592
3,099
2,723
2,437
2,546
2,877
2,348
2,143
2,582
3,214
3,2142,5822,1432,3482,8772,5462,4372,7233,0996,5923,6193,2322,9932,2263,16710,0679,0838,9679,1539,2804,2223,1813,912
       Short-term Debt 
0
0
0
6,412
6,536
6,674
6
0
0
69
205
0
0
0
0
0
0
0
0
0
0
0
0
000000000000205690066,6746,5366,412000
       Short Long Term Debt 
0
0
0
6,412
6,536
6,674
6
0
0
69
205
0
0
0
0
0
0
0
0
0
0
0
0
000000000000205690066,6746,5366,412000
       Accounts payable 
1,149
697
1,021
1,156
952
796
944
1,555
1,411
986
1,503
1,450
1,430
760
906
557
629
1,158
828
849
503
814
714
7148145038498281,1586295579067601,4301,4501,5039861,4111,5559447969521,1561,0216971,149
       Other Current Liabilities 
2,764
2,484
2,378
1,712
813
1,497
307
1,555
238
769
5
843
661
5,607
671
1,941
382
1,192
295
1,372
303
1,476
820
8201,4763031,3722951,1923821,9416715,60766184357692381,5553071,4978131,7122,3782,4842,764
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
646
851
806
741
687
625
563
496
474
452
429
400
769
740
740769400429452474496563625687741806851646000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-6,412
-6,536
-6,674
-6
0
0
599
599
973
913
867
807
744
683
634
577
520
460
1,020
1,006
1,0061,02046052057763468374480786791397359959900-6-6,674-6,536-6,412000
       Other Liabilities 
94
110
155
99
43
43
43
44
47
47
47
48
44
45
44
44
36
36
36
36
31
41
48
484131363636364444454448474747444343439915511094
> Total Stockholder Equity
15,214
13,119
8,470
13,005
10,577
7,685
5,040
2,377
18,613
15,785
11,703
8,925
9,629
6,272
7,317
5,544
3,864
6,479
6,361
24,234
22,120
19,087
16,666
16,66619,08722,12024,2346,3616,4793,8645,5447,3176,2729,6298,92511,70315,78518,6132,3775,0407,68510,57713,0058,47013,11915,214
   Common Stock
23,980
24,316
22,735
24,014
24,014
24,014
24,014
24,014
36,022
36,022
36,022
36,022
43,528
43,528
47,130
47,130
5,891
5,891
11,823
12,232
15,540
15,980
16,357
16,35715,98015,54012,23211,8235,8915,89147,13047,13043,52843,52836,02236,02236,02236,02224,01424,01424,01424,01424,01422,73524,31623,980
   Retained Earnings -97,117-95,817-93,160-91,423-94,260-91,933-90,732-111,936-109,181-105,808-102,827-95,817-93,223-88,825-85,807-81,861-78,888-76,334-73,115-70,493-69,354-69,788-66,323
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
57,555
58,591
55,089
59,484
59,678
60,005
59,914
60,224
68,398
68,588
68,904
68,720
68,928
68,552
69,368
70,350
88,705
92,521
88,798
103,425
99,740
98,924
97,426
97,42698,92499,740103,42588,79892,52188,70570,35069,36868,55268,92868,72068,90468,58868,39860,22459,91460,00559,67859,48455,08958,59157,555



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue6,203
Cost of Revenue-136
Gross Profit6,0676,067
 
Operating Income (+$)
Gross Profit6,067
Operating Expense-10,365
Operating Income-4,162-4,298
 
Operating Expense (+$)
Research Development3,111
Selling General Administrative4,437
Selling And Marketing Expenses-
Operating Expense10,3657,548
 
Net Interest Income (+$)
Interest Income12
Interest Expense-52
Net Interest Income-56-40
 
Pretax Income (+$)
Operating Income-4,162
Net Interest Income-56
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-2,410-4,162
EBIT - interestExpense = -4,214
-2,410
-2,376
Interest Expense52
Earnings Before Interest and Taxes (ebit)-4,162-2,358
Earnings Before Interest and Taxes (ebitda)-1,939
 
After tax Income (+$)
Income Before Tax-2,410
Tax Provision-18
Net Income From Continuing Ops-2,428-2,428
Net Income-2,428
Net Income Applicable To Common Shares-2,428
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-391
Total Other Income/Expenses Net-56
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ICGA.F
1 minute ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ICGA.F.

ICGA.F Daily Candlestick Chart
UPAB.AS
4 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of UPAB.AS.

UPAB.AS Daily Candlestick Chart
PFE.XETRA
24 minutes ago

I found you a Death Cross on the daily chart of PFE.XETRA.

PFE.XETRA Daily Candlestick Chart
IS0X.XETRA
30 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of IS0X.XETRA.

IS0X.XETRA Daily Candlestick Chart
IS0S.XETRA
30 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of IS0S.XETRA.

IS0S.XETRA Daily Candlestick Chart
XUEK.XETRA
32 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XUEK.XETRA.

XUEK.XETRA Daily Candlestick Chart
IBC9.XETRA
32 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of IBC9.XETRA.

IBC9.XETRA Daily Candlestick Chart
XMK9.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XMK9.XETRA.

XMK9.XETRA Daily Candlestick Chart
XAIX.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XAIX.XETRA.

XAIX.XETRA Daily Candlestick Chart
EUN1.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of EUN1.XETRA.

EUN1.XETRA Daily Candlestick Chart
EMNE.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of EMNE.XETRA.

EMNE.XETRA Daily Candlestick Chart
DX2D.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of DX2D.XETRA.

DX2D.XETRA Daily Candlestick Chart
36B5.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 36B5.XETRA.

36B5.XETRA Daily Candlestick Chart
AWSR.LSE
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of AWSR.LSE.

AWSR.LSE Daily Candlestick Chart
AWSG.LSE
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of AWSG.LSE.

AWSG.LSE Daily Candlestick Chart
CI2U.LSE
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of CI2U.LSE.

CI2U.LSE Daily Candlestick Chart
VFEM.LSE
34 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of VFEM.LSE.

VFEM.LSE Daily Candlestick Chart
ROBO.LSE
34 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ROBO.LSE.

ROBO.LSE Daily Candlestick Chart
ARIX.LSE
34 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ARIX.LSE.

ARIX.LSE Daily Candlestick Chart
UETW.XETRA
37 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of UETW.XETRA.

UETW.XETRA Daily Candlestick Chart
PLUN.XETRA
37 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PLUN.XETRA.

PLUN.XETRA Daily Candlestick Chart
LYYA.XETRA
37 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of LYYA.XETRA.

LYYA.XETRA Daily Candlestick Chart
IUSP.XETRA
37 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of IUSP.XETRA.

IUSP.XETRA Daily Candlestick Chart
SXR3.XETRA
37 minutes ago

I found you a Death Cross on the daily chart of SXR3.XETRA.

SXR3.XETRA Daily Candlestick Chart
EDM4.XETRA
37 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of EDM4.XETRA.

EDM4.XETRA Daily Candlestick Chart